Groundbreaking Swedish research shows no signs of waning protection up to 18 years after vaccination, supporting continued global immunisation strategies.
A major study published in The BMJ has confirmed that the quadrivalent human papillomavirus (HPV) vaccine provides sustained protection against invasive cervical cancer for at least 18 years, with no evidence of protection weakening over time. The findings, published on 25 February 2026, provide significant reassurance for millions of women worldwide who have received the vaccine and strengthen the case for continued vaccination programmes globally.
The Swedish research, conducted by scientists at Karolinska Institutet in collaboration with the Public Health Agency of Sweden, examined data from over 926,000 girls and women born between 1985 and 2001. The study tracked participants over an 18-year follow-up period from 2006 to 2023, making it one of the longest-term evaluations of HPV vaccine effectiveness to date.
Outstanding Protection for Early Vaccination
The results demonstrate particularly strong protection for girls vaccinated before age 17. This group experienced a 79 per cent lower risk of developing invasive cervical cancer compared to unvaccinated women. Remarkably, this protection remained consistent even 13 to 15 years after vaccination, with researchers finding no indication of declining immunity as vaccinated girls reached adulthood—the age when cervical cancer typically develops.
Women vaccinated at age 17 or older also showed significant protection, with a 37 per cent lower risk compared to unvaccinated individuals. After 10 to 12 years, their protection increased to 46 per cent, and after 13 to 15 years, it rose to 77 per cent. During the follow-up period, 930 cases of invasive cervical cancer were identified across the entire cohort: just 97 cases occurred in vaccinated individuals, whilst 833 occurred in unvaccinated women.
What the Findings Mean for Immunity
Human papillomavirus is one of the most common sexually transmitted infections worldwide. Certain strains of HPV can lead to cervical cancer and other related cancers in both men and women. The quadrivalent vaccine protects against four HPV types, including the two most dangerous strains associated with cervical cancer.
The sustained protection observed in this study has important implications for vaccine strategy. According to researchers including Shiqiang Wu, doctoral student at Karolinska Institutet’s Department of Medical Epidemiology and Biostatistics, “It is encouraging that the protection persists as young girls become adults and reach the ages when cervical cancer often occurs. This suggests that no booster doses of the HPV vaccine are needed at present.”
The study’s large scale and real-world setting—using national health registry data rather than a controlled trial—provide robust evidence of vaccine effectiveness in everyday circumstances. Researchers accounted for numerous influential factors including age, county of residence, parental education, income, and medical history to strengthen their findings.
Population-Level Impact
Beyond individual protection, the research documents a notable population-level decline in cervical cancer cases since HPV vaccination programmes were introduced in Sweden. This represents a significant public health achievement and suggests that as vaccination coverage increases, cervical cancer rates continue to fall.
The researchers acknowledge certain limitations of their observational study. Some vaccinated women may have been misclassified as unvaccinated, and lifestyle factors such as smoking and sexual activity—not available in registry data—could potentially have influenced results. However, the consistency of findings across multiple time intervals since vaccination suggests the results are robust.
Global Implications
The study provides compelling evidence for countries considering or expanding HPV vaccination programmes. According to the researchers, these findings “further support global strategies for eliminating cervical cancer as a public health problem by achieving high coverage of routine HPV vaccination, particularly in younger populations.”
The World Health Organisation has identified cervical cancer elimination as an achievable goal through vaccination, screening, and treatment, with HPV vaccination playing a crucial role, particularly for girls aged 9 to 14 years before potential exposure to the virus.
Next steps for researchers include investigating how vaccination rates can be further improved and studying how the vaccine protects against other HPV-related cancers in both women and men. Continued follow-up studies will also examine different vaccination schedules and long-term effectiveness beyond the current 18-year observation period.
Source: @bmj_latest
Key Takeaways
- Girls vaccinated against HPV before age 17 experienced a 79 per cent reduction in invasive cervical cancer risk with sustained protection over 18 years
- No indication of waning immunity was observed at any point during the follow-up period, suggesting booster doses are not currently needed
- The study strengthens the case for universal HPV vaccination programmes as a strategy for eliminating cervical cancer as a public health problem
What This Means for Kent Residents
In the UK, the HPV vaccine has been offered routinely through the NHS cervical screening programme since 2008. Girls aged 12 to 13 years are typically offered the vaccine through their school, with catch-up vaccinations available for older teenagers. This Swedish evidence supports the UK’s continued commitment to high vaccination coverage.
Kent residents aged 12 to 26 years who haven’t received the vaccine can ask their GP practice about access. Those with questions about HPV vaccination or cervical cancer screening can contact their local NHS GP surgery or the NHS cervical screening programme. The NHS England website and Kent and Medway NHS Trust provide further information about local sexual health services and vaccination clinics throughout the county.
